FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
RegulatoryapprovedTecentriqTecentriq HybrezaPositive
AI Analysis
Summary
The FDA approved Roche's Tecentriq and Tecentriq Hybreza in combination with fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III dMMR colon cancer, marking the drug's twelfth US indication.
Outcome Details
FDA approved Tecentriq and Tecentriq Hybreza in combination with fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III dMMR colon cancer. This is the twelfth indication for Tecentriq in the US.
Importance:8/10
Sentiment:
0.90
FDA approvaloncologycolon canceradjuvant therapyimmunotherapy
Related Companies
Read the original article
Published by GlobeNewswire Pharma on October 9, 2026 5:00 AM